What is the recommended treatment approach for allergic rhinitis in infants?

Treatment of Allergic Rhinitis in Infants

For infants with allergic rhinitis, use second-generation oral antihistamines (cetirizine, loratadine, or desloratadine) as first-line pharmacologic therapy, combined with saline nasal irrigation; avoid over-the-counter decongestants and first-generation antihistamines entirely due to documented fatalities in this age group. 1

Critical Safety Considerations in Infants

Avoid all OTC decongestants and first-generation antihistamines in children under 6 years:

• Between 1969-2006, there were 54 fatalities from decongestants (pseudoephedrine, phenylephrine, ephedrine) in children ≤6 years, with 43 deaths occurring in infants under 1 year of age 1
• During the same period, 69 fatalities occurred from first-generation antihistamines (diphenhydramine, brompheniramine, chlorpheniramine), with 41 deaths in children under 2 years 1
• The FDA's Nonprescription Drugs and Pediatric Advisory Committees recommended against OTC cough and cold medications for all children below 6 years of age 1

First-Line Pharmacologic Treatment

Second-generation antihistamines are safe and effective in infants:

• Cetirizine, desloratadine, fexofenadine, levocetirizine, and loratadine have demonstrated excellent safety profiles and tolerability in young children 1
• These agents effectively control sneezing, itching, and rhinorrhea 1
• They do not carry the toxicity risks associated with first-generation antihistamines or decongestants 1

Intranasal Corticosteroids: Age-Specific Limitations

Intranasal corticosteroids are the most effective medication class for allergic rhinitis but have age restrictions:

• Most intranasal corticosteroids are FDA-approved only for children ≥2 years of age 2
• Triamcinolone acetonide is approved for children ≥2 years 2
• Mometasone furoate and fluticasone furoate are approved for children ≥2 years 2
• For infants under 2 years, intranasal corticosteroids are generally not indicated due to lack of FDA approval in this age group 2

Non-Pharmacologic Management

Saline nasal irrigation is safe, effective, and recommended for all ages:

• Nasal lavage with physiological saline followed by gentle aspiration is effective for nasal congestion in term and preterm neonates and infants 3
• This approach is particularly important since infants are obligate nasal breathers until at least 2 months of age 3
• Saline irrigation removes secretions, allergens, and inflammatory mediators without medication risks 3, 4

Environmental allergen avoidance is essential:

• Identify and minimize exposure to specific allergen triggers (dust mites, pet dander, mold) 1
• Use dust mite covers for bedding, maintain low humidity, and employ HEPA filtration 1

Leukotriene Receptor Antagonists

Montelukast is FDA-approved for perennial allergic rhinitis in infants ≥6 months:

• Montelukast is safe and effective for managing allergic rhinitis in young children 1
• It is approved for perennial allergic rhinitis in children as young as 6 months and seasonal allergic rhinitis in children ≥2 years 1
• However, montelukast is less effective than intranasal corticosteroids and should not be used as first-line therapy when intranasal corticosteroids are appropriate 5, 1
• Consider montelukast when coexisting asthma is present, as it benefits both upper and lower airway disease 1

Treatment Algorithm for Infants

1. Initiate allergen avoidance measures and regular saline nasal irrigation 1, 3

2. Start a second-generation oral antihistamine (cetirizine or loratadine at age-appropriate dosing) 1

3. For infants ≥6 months with persistent symptoms, consider adding montelukast, particularly if there is coexisting lower respiratory involvement 1

4. For children ≥2 years with inadequate control, escalate to intranasal corticosteroids (mometasone, fluticasone furoate, or triamcinolone) 2, 6

5. Re-evaluate after 2-4 weeks; if symptoms remain uncontrolled despite appropriate therapy, refer to pediatric allergist for evaluation and possible immunotherapy 6

Common Pitfalls to Avoid

• Never use topical nasal decongestants (oxymetazoline, phenylephrine) for more than 3 days due to risk of rhinitis medicamentosa 6
• Never prescribe OTC first-generation antihistamines or decongestants in children under 6 years due to documented mortality risk 1
• Do not use antihistamine-decongestant combinations, as they are ineffective for upper respiratory infections in young children and carry toxicity risks 1
• Recognize that true allergic rhinitis is uncommon in the first year of life; consider alternative diagnoses such as viral rhinitis or milk/soy protein allergy 3, 7